Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kenyan adult malaria vaccine candidate safety and efficacy study
PACTR202108505632810Phase 2Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of R21/Matrix-M, ChAd63/MVA ME-TRAP and PfSPZ Challenge in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Safety, Efficacy and 1 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
R21/Matrix-MChAd63/MVA ME-TRAPPfSPZ Challenge
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202108505632810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202108505632810.